RG-002-C-0106

N/A

Report date: 2026/03/15 20:00:14
NME

Base Information

Drug NameRG-002-C-0106
Drug Alias NameRG002C0106RG-002-C-0106
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsComplement-Mediated DiseasesHemolysisNephrotic Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Xuanjingrui Pharmaceutical Technology Co LtdSuzhou Xuanjing Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Xuanjing Biotechnology Co LtdBeijing Xuanjingrui Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsComplement-Mediated DiseasesHemolysisNephrotic Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A